PL413921A1 - Zestaw farmaceutyczny oraz zastosowanie erytropoetyny oraz inhibitora kinazy Brutona - Google Patents
Zestaw farmaceutyczny oraz zastosowanie erytropoetyny oraz inhibitora kinazy BrutonaInfo
- Publication number
- PL413921A1 PL413921A1 PL413921A PL41392115A PL413921A1 PL 413921 A1 PL413921 A1 PL 413921A1 PL 413921 A PL413921 A PL 413921A PL 41392115 A PL41392115 A PL 41392115A PL 413921 A1 PL413921 A1 PL 413921A1
- Authority
- PL
- Poland
- Prior art keywords
- erythropoietin
- application
- kinase inhibitor
- bruton kinase
- bruton
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Przedmiotem zgłoszenia jest zestaw farmaceutyczny charakteryzujący się tym, że zawiera erytropoetynę oraz inhibitor kinazy Brutona, zarówno w tym samym lub odrębnym opakowaniu i/lub instrukcję stosowania. Dodatkowo przedmiotem zgłoszenia jest także erytropoetyna oraz inhibitor kinazy Brutona do zastosowania jako lek. Ponadto, przedmiotem zgłoszenia jest zastosowanie erytropoetyny oraz inhibitora kinazy Brutona do wytwarzania leku do terapii nowotworu.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL413921A PL230756B1 (pl) | 2015-09-11 | 2015-09-11 | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
PCT/IB2016/055347 WO2017042706A1 (en) | 2015-09-11 | 2016-09-08 | Pharmaceutical kit and use of erythropoietin and bruton's kinase inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL413921A PL230756B1 (pl) | 2015-09-11 | 2015-09-11 | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
Publications (2)
Publication Number | Publication Date |
---|---|
PL413921A1 true PL413921A1 (pl) | 2017-03-13 |
PL230756B1 PL230756B1 (pl) | 2018-12-31 |
Family
ID=57233782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL413921A PL230756B1 (pl) | 2015-09-11 | 2015-09-11 | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL230756B1 (pl) |
WO (1) | WO2017042706A1 (pl) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US6171620B1 (en) * | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
US20030083250A1 (en) * | 2001-10-25 | 2003-05-01 | Francis Farrell | Anti-tumor chemotherapy by administration of cyclophosphamide and erythropoeitin |
RS53165B (en) * | 2007-03-14 | 2014-06-30 | Bionsil S.R.L. | BTK INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT EPITHELIC TUMORS |
-
2015
- 2015-09-11 PL PL413921A patent/PL230756B1/pl unknown
-
2016
- 2016-09-08 WO PCT/IB2016/055347 patent/WO2017042706A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
PL230756B1 (pl) | 2018-12-31 |
WO2017042706A1 (en) | 2017-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253995A0 (en) | Pharmaceutical formulations of proton tyrosine kinase inhibitor | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
EA201691114A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
EA202092456A3 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
WO2016100347A3 (en) | Small molecule inhibitors of egfr and pi3k | |
EP3405192A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
EA202090683A3 (ru) | Способы и композиции для лечения рака | |
HK1258699A1 (zh) | 包含酪氨酸蛋白激酶抑制劑的劑型組合物 | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
EA201792157A1 (ru) | Имидазопиразиноны в качестве ингибиторов pde1 | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
EP3328380A4 (en) | INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
IT201700025666A1 (it) | Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari. | |
MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
PL420267A1 (pl) | Ekstrakt z grzyba poliporoidalnego, kompozycja zawierająca ten ekstrakt oraz jego zastosowanie | |
EP3412657A4 (en) | NEW IRREVERSIBLE INHIBITOR OF BRUTON TYROSINE KINASE |